Marie-Paule Guillaume
Marie-Paule Guillaume has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Guy Vaksmann
Department of Pediatric Cardiology, Hôpital Privé de La Louvière, Lille, France
2 shared publications A. Richard
Hôpital Privé de La Louvière, Lille, France
1 shared publication- Adélaïde Richard
Department of Paediatric Cardiology, Hôpital privé La Louvière, Lille, France
1 shared publication - Bouzguenda Ivan
Department of Paediatric Cardiology, Hôpital privé La Louvière, Lille, France
1 shared publication - François Godart
Paediatric and Congenital Cardiology Department, Heart and Lung Institute, University Hospital of Lille , Lille 59000
1 shared publication I. Bouzguenda
Hôpital Privé de La Louvière, Lille, France
1 shared publication
Latest Publications
- 7 September 2023
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 15 (4) , 277
Prevalence and consequences of mitral annular disjunction and Pickelhaude sign in children with mitral valve prolapse
- 7 September 2023
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 15 (4) , 277
Prevalence and consequences of mitral annular disjunction and Pickelhaude sign in children with mitral valve prolapse
- 29 October 2020
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 180 (4) , 1157-1167
Screening for neurodevelopmental disorders in children with congenital heart disease
The aim of this study was to evaluate the frequency of neurodevelopmental disorders (NDD) in children with significant congenital heart disease (CHD) and to determine associated factors to NDD and frequency of follow-up in developmental therapies. Two hundred and ten children with significant CHD aged from 6 to 66 months were enrolled over a period of six months. The Ages & Stages Questionnaire Third Edition in French (ASQ-3) was used to assess neurodevelopmental domains. NDD were defined if cut-off scores were ≤ − 1SD. – 1SD corresponded to “Monitor” range: children with minor or emerging disorders; − 2SD corresponded to “Refer” range: children exhibiting neurodevelopmental delays. Forty children were in “Monitor” range and 86 in “Refer” range. NDD rate was 60.0% (n = 126, 95% CI, 53.4 to 66.6%). There was no difference regarding CHD severity (p = 0.99). Only the presence of non-cardiac disease (OR = 2.14; 95% CI, 1.11 to 4.20) was associated with NDD. Forty-six children with NDD had no developmental follow-up (among them 21 were in “Refer” range (10%)) despite this being available. Conclusion: Children with significant CHD are at risk for NDD regardless of CHD severity. Systematic and early monitoring in a specific care program is required. Barriers that prevent access of care must be identified. Trial registration: Neurodevelopmental Disorders in Children With Congenital Heart Disease. NeuroDis-CHD. NCT03360370. https://clinicaltrials.gov/ct2/show/NCT03360370 What is Known: • Children with CHD are at risk for neurodevelopmental disorders and behavioural problems impacting their social adaptation, academic achievements and quality of personal and family life even in adulthood. What is New: • Children with CHD are at risk for neurodevelopmental disorders regardless of the complexity of the CHD. • Even with the availability of appropriate developmental services, children with CHD are not correctly followed, highlighting the need of a specific program of care for a better outcome. Local barriers that prevent access of care of those children must be identified.
- 29 October 2020
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 180 (4) , 1157-1167
Screening for neurodevelopmental disorders in children with congenital heart disease
The aim of this study was to evaluate the frequency of neurodevelopmental disorders (NDD) in children with significant congenital heart disease (CHD) and to determine associated factors to NDD and frequency of follow-up in developmental therapies. Two hundred and ten children with significant CHD aged from 6 to 66 months were enrolled over a period of six months. The Ages & Stages Questionnaire Third Edition in French (ASQ-3) was used to assess neurodevelopmental domains. NDD were defined if cut-off scores were ≤ − 1SD. – 1SD corresponded to “Monitor” range: children with minor or emerging disorders; − 2SD corresponded to “Refer” range: children exhibiting neurodevelopmental delays. Forty children were in “Monitor” range and 86 in “Refer” range. NDD rate was 60.0% (n = 126, 95% CI, 53.4 to 66.6%). There was no difference regarding CHD severity (p = 0.99). Only the presence of non-cardiac disease (OR = 2.14; 95% CI, 1.11 to 4.20) was associated with NDD. Forty-six children with NDD had no developmental follow-up (among them 21 were in “Refer” range (10%)) despite this being available. Conclusion: Children with significant CHD are at risk for NDD regardless of CHD severity. Systematic and early monitoring in a specific care program is required. Barriers that prevent access of care must be identified. Trial registration: Neurodevelopmental Disorders in Children With Congenital Heart Disease. NeuroDis-CHD. NCT03360370. https://clinicaltrials.gov/ct2/show/NCT03360370 What is Known: • Children with CHD are at risk for neurodevelopmental disorders and behavioural problems impacting their social adaptation, academic achievements and quality of personal and family life even in adulthood. What is New: • Children with CHD are at risk for neurodevelopmental disorders regardless of the complexity of the CHD. • Even with the availability of appropriate developmental services, children with CHD are not correctly followed, highlighting the need of a specific program of care for a better outcome. Local barriers that prevent access of care of those children must be identified.
- 1 January 2007
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 27 (10) , 727-729
First Use of Tamoxifen in an HIV??Patient with Encapsulating Peritoneal Sclerosis
Encapsulating peritoneal sclerosis (EPS) is a rare but serious life-threatening complication in peritoneal dialysis patients. At present, there is no evidence-based standard therapy for EPS. Tamoxifen has been used and shown good results in non-HIV peritoneal dialysis patients with EPS. We report a case of a patient with HIV treated with antiretroviral therapy (zidovudine, lamivudine and saquinavir) for several years. He had end-stage renal disease and was treated with continuous ambulatory peritoneal dialysis (CAPD). After 11 years on CAPD, he developed EPS and was treated successfully with tamoxifen in combination with corticosteroids. No adverse effects were observed and no changes were noted in CD4 counts or HIV viral load during this therapy. These findings suggest that tamoxifen can be safely given to HIV patients with peritoneal dialysis-related EPS. Nevertheless, caution is required as tamoxifen could interact with certain antiretroviral agents.
- 1 January 2007
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 27 (10) , 727-729
First Use of Tamoxifen in an HIV??Patient with Encapsulating Peritoneal Sclerosis
Encapsulating peritoneal sclerosis (EPS) is a rare but serious life-threatening complication in peritoneal dialysis patients. At present, there is no evidence-based standard therapy for EPS. Tamoxifen has been used and shown good results in non-HIV peritoneal dialysis patients with EPS. We report a case of a patient with HIV treated with antiretroviral therapy (zidovudine, lamivudine and saquinavir) for several years. He had end-stage renal disease and was treated with continuous ambulatory peritoneal dialysis (CAPD). After 11 years on CAPD, he developed EPS and was treated successfully with tamoxifen in combination with corticosteroids. No adverse effects were observed and no changes were noted in CD4 counts or HIV viral load during this therapy. These findings suggest that tamoxifen can be safely given to HIV patients with peritoneal dialysis-related EPS. Nevertheless, caution is required as tamoxifen could interact with certain antiretroviral agents.